The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy: The allergen challenge chamber and pollen immunotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The clinical development of allergen immunotherapy for allergic rhinoconjunctivitis because of pollen is complicated by seasonal, geographical and subject-related variability in allergen exposure. Using an allergen challenge chamber (ACC), a room that enables reproducible challenges with controlled levels of inhalant allergens for several hours, these factors can be controlled. The ACC has often been used to evaluate symptomatic medications but is underexploited in the field of allergen immunotherapy. When used in conjunction with a programme of natural-exposure trials, the ACC enables researchers to (i) facilitate the allergen immunotherapy dose-finding process, (ii) accelerate the transition from Phase I/II to Phase III trials, (iii) characterize the onset and maintenance of action, (iv) avoid the confounding effects of rescue medication, (v) better characterize the baseline or pretreatment characteristics of trial subjects, (vi) perform better-standardized physical and laboratory measurements during an acute challenge, (vii) simplify trial logistics and use smaller numbers of subjects than would be required in equivalent natural-exposure studies and (viii) support (but not replace) Phase III natural-exposure trials for the investigation into long-term and disease-modifying effects. ACC studies can further increase levels of evidence for allergen immunotherapy--the only current therapy potentially capable of modifying the underlying allergic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729 · cited 1×
“Allergen immunotherapy is used with clinical success in reorienting inappropriate immune responses in allergic patients (1).”
BackgroundAllergen injection immunotherapy for seasonal allergic rhinitis
Calderon, M. A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., & Durham, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001936.pub2 · Cited by 678 · cited 2×
“Lastly, in terms of safety, SCIT is accompanied by a nonnegligible risk of potentially fatal adverse events (4, 11).”
BackgroundSublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis*
Wilson, D. R., Torres Lima, M., & Durham, S. R. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00699.x · Cited by 660 · cited 2×
“Although the 2005 Cochrane Collaboration meta-analysis (5) failed to observe efficacy in children, two separate meta-analyses of, respectively, 7 and 10 paediatric SLIT trials in seasonal allergic rhinitis published at around the same time concluded as to a significant reduction in the overall symptom score and in res…”
BackgroundHorak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Devillier, P., Montagut, A., Mélac, M., Galvain, S., Jean-Alphonse, S., Van Overtvelt, L., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.006 · Cited by 175 · cited 7×
“Using an ACC, a single group of patients can be challenged repeatedly over time to identify the treatment’s onset of action (13).”
BackgroundMethodSelf-citationHorak, F., Petra Zieglmayer, U., Zieglmayer, R., Kavina, A., Marschall, K., Munzel, U., & Petzold, U. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80305 · Cited by 98
Self-citationKrug, N., Loedding, H., Hohlfeld, J. M., Larbig, M., Buckendahl, A., Badorrek, P., Geldmacher, H., Behnke, W., Dunkhorst, W., Windt, H., et al. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01810.x · Cited by 73
Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802155792 · Cited by 35
Self-citation
Cited by
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Canonica, G. W., Cox, L., Pawankar, R., Baena-Cagnani, C. E., Blaiss, M., Bonini, S., Bousquet, J., Calderón, M., Compalati, E., Durham, S. R., et al. (2014) · World Allergy Organization Journal · doi:10.1186/1939-4551-7-6 · Cited by 591
Nolte, H., Maloney, J., Nelson, H. S., Bernstein, D. I., Lu, S., Li, Z., Kaur, A., Zieglmayer, P., Zieglmayer, R., Lemell, P., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1911 · Cited by 160
Self-citationIn vivo diagnosis of allergic diseases-allergen provocation tests
Agache, I., Bilò, M., Braunstahl, G.-J., Delgado, L., Demoly, P., Eigenmann, P., Gevaert, P., Gomes, E., Hellings, P., Horak, F., et al. (2015) · Allergy · doi:10.1111/all.12586 · Cited by 104
Self-citationPatel, P., Holdich, T., Fischer von Weikersthal-Drachenberg, K. J., & Huber, B. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.032 · Cited by 98
Meyer, W., Narkus, A., Salapatek, A. M., & Häfner, D. (2013) · Allergy · doi:10.1111/all.12148 · Cited by 72
“Due to reduced variability of data produced in the EEC, the outcomes of treatment can be determined with smaller sample sizes as compared with, for example, field based studies (17).”
Metadata
- Authors
- Devillier, P., Le Gall, M., & Horak, F.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2010-10-06
- Volume
- 66
- Issue
- 2
- Pages
- 163-169
- ISSN
- 0105-4538 (ISSN-L)
- OpenAlex
- W1516952736
- Cited by
- 58
- References
- 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy: The allergen challenge chamber and pollen immunotherapy. https://app.cochat.ai/papers/10.1111/j.1398-9995.2010.02473.x
- The paper
- Devillier, P., Le Gall, M., & Horak, F. (2011). The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy: The allergen challenge chamber and pollen immunotherapy. Allergy. https://doi.org/10.1111/j.1398-9995.2010.02473.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.